# Advancing Diagnosis of Liver Cirrhosis: Why Non-invasive Methods Are the Future?

## TL;DR

Non-invasive methods for diagnosing liver cirrhosis are becoming more accurate and practical, offering safer and cost-effective alternatives to traditional invasive techniques.

## Contribution

This review highlights recent advancements in non-invasive diagnostic tools and their potential to replace invasive methods in clinical practice.

## Key findings

- Non-invasive methods like serum biomarkers and elastography show high accuracy in detecting liver cirrhosis.
- Emerging technologies such as AI-driven radiomics and multimodal approaches improve early detection and diagnostic accuracy.
- Non-invasive methods are increasingly recommended in clinical guidelines, especially for metabolic dysfunction-associated liver disease.

## Abstract

Liver cirrhosis is the irreversible end-stage of chronic liver disease and remains a significant health burden to the global society. Although traditional methods, such as liver biopsy and hepatic venous pressure gradient (HVPG) measurement, are considered the gold standard, they are limited by bleeding, sampling variability, and patient discomfort. This review explores recent advancements in non-invasive methods (NIMs) for diagnosing and monitoring cirrhosis.

The primary NIMs include serum biomarkers (e.g., Enhanced Liver Fibrosis {ELF} test, Fibrosis-4 {FIB-4} index), which allow for dynamic monitoring of fibrosis progression, and elastography techniques (e.g., vibration-controlled transient elastography {VCTE}, magnetic resonance elastography {MRE}), which demonstrate high accuracy in detecting advanced fibrosis. Further improving diagnostic accuracy and early detection are emerging technologies, such as AI-driven radiomics and multimodal techniques that combine imaging with genetic and epigenetic markers (e.g., circulating cell-free DNA). Despite its benefits - safety, cost-effectiveness, and reproducibility - NIMs have drawbacks, including inconsistent outcomes due to obesity and unequal availability throughout the world. NIMs are increasingly recommended as first-line tools in clinical guidelines, especially in metabolic dysfunction-associated steatotic liver disease (MASLD). To close implementation gaps in the real world, future developments will focus on standardization, point-of-care devices, and the integration of machine learning models. This review emphasizes NIMs as the foundation of a precision hepatology paradigm that is patient-centered. They are poised to replace invasive techniques as standard practice, lowering costs and improving results.